Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated pseudomonas exotoxin A

Journal of Immunotherapy

Volumn 24, Issue 2, 2001, Pages 144-150

  Onda, M ^a   Olafsen, T ^a   Tsutsumi, Y ^a   Bruland, O S ^a   Pastan, I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Fv; Immunotoxin; Osteosarcoma; Pseudomonas exotoxin; TP 3

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOTOXIN TP3(DSFV)PE38; IMMUNOTOXIN TP3(SCFV)PE38; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TP1; MONOCLONAL ANTIBODY TP3; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; RECOMBINANT IMMUNOTOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TOLERABILITY; GENE FUSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PSEUDOMONAS; TOXIN ANALYSIS;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; BACTERIAL TOXINS; CELL DEATH; DRUG STABILITY; EXOTOXINS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTOXINS; MICE; OSTEOSARCOMA; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; VIRULENCE FACTORS;

EID: 0035119540     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200103000-00009     Document Type: Article

References (38)

1. Immunotoxins for targeted cancer therapy
2. The α2-macrglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A
3. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution
4. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli
5. Immunotoxins against cancer
6. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis
7. Pediatric osteosarcoma: Therapeutic strategies, results, and prognostic factors derived from a 10-year experience
8. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience
9. Osteogenic sarcoma with clinically detectable metastasis at initial presentation
10. Pulmonary metastases of stage 11B extremity osteosarcoma and subsequent pulmonary metastases
11. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group
12. Multidrug resistance - A multiplex phenomenon
13. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy
14. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study
15. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma
16. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide
17. erbB-2 expression is correlated with poor prognosis for patients with osteosarcoma
18. Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen
19. Selective localization of two radiolabelled anti-sarcoma monoclonal antibodies in human osteosarcoma xenografts
20. New monoclonal antibodies specific for human sarcomas
21. Immunohistochemical detection of osteosarcoma-associated antigen in canine osteosarcoma
22. Immunoscintigraphic detection of primary and metastatic spontaneous canine osteosarcoma with F(ab')2 fragments of osteosarcoma-associated monoclonal antibody TP-1
23. PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment
24. Immunoscintigraphy of bone sarcomas - Results in 5 patients
25. Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling
26. Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cell
27. IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells
28. Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies
29. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment
30. Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma
31. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point
32. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice
33. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin
34. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes
35. A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies
36. In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein
37. Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: Comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays
38. Improving antibody affinity by mimicking somatic hypermutation in vitro